Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

Arsela Prelaj; Rebecca Tay; Roberto Ferrara; Nathalie Chaput; Benjamin Besse; Raffaele Califano

doi:10.1016/j.ejca.2018.11.002

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

Eur J Cancer. 2019 Jan:106:144-159. doi: 10.1016/j.ejca.2018.11.002. Epub 2018 Dec 5.

Authors

Arsela Prelaj¹, Rebecca Tay², Roberto Ferrara³, Nathalie Chaput⁴, Benjamin Besse⁵, Raffaele Califano⁶

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Radiological, Pathological and Oncological Science, Sapienza University of Rome, Italy. Electronic address: arsela20@hotmail.it.
² Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: rebecca.tay@christie.nhs.uk.
³ Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France. Electronic address: roberto.ferrara@gustaveroussy.fr.
⁴ Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France; Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France. Electronic address: nathalie.chaput@gustaveroussy.fr.
⁵ Cancer Medicine Department, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: benjamin.besse@gustaveroussy.fr.
⁶ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: raffaele.califano@christie.nhs.uk.

PMID: 30528799
DOI: 10.1016/j.ejca.2018.11.002

Abstract

Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.

Keywords: Immunotherapy; Lung cancer; Microsatellite instability; NSCLC; PD-L1; Predictive biomarkers; Tumour microenvironment; Tumour mutational burden.

Publication types

Review

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
B7-H1 Antigen / immunology
Biomarkers, Tumor / antagonists & inhibitors*
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / immunology
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Mutation
Predictive Value of Tests
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Risk Assessment
Risk Factors
Signal Transduction
Transcriptome
Treatment Outcome
Tumor Microenvironment

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
Biomarkers, Tumor
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor